5 Questions With, Cassandra Pollard, Quality Control Associate II, Charles River Laboratories Cassandra Pollard is an alumni of the UMBC translational life science technologies program and a member of our [….]
Harder, Better, Faster, Stronger – How AAVs Went From Lab to Clinic, and How Charles Rivers’ nAAVigation™ Platform Helps Scientists Take Gene Therapy From Science Fiction to Life-Saving Cures By [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of March 20, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryMarch 24, 2023 Funding, Awards and Collaborations MacroGenics Earns $15 Million [….]
A recent panel discussion at Bisnow’s May Mid-Atlantic Life Sciences & Biotech event further emphasized the point that we’ve been hearing time and time again – we need to do more to support and adequately prepare the workforce to fill not only the current life science positions but future needs as well.
If you’re a scientist, chances are when you hear the name “Charles River Laboratories” (Charles River) you may initially think of their industry-leading research models which are a staple for research labs globally. But did you also know that Charles River offers a plethora of products and services for translational laboratories and life science companies alike that span across the drug development lifecycle?
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional payments of up to $57.5 million, contingent on future performance.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.
